Adial Pharmaceuticals (ADIL) Competitors $0.51 +0.03 (+7.04%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.54 +0.03 (+4.86%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. LEXX, HOOK, NEUP, ERNA, SYBX, BFRG, MTVA, BCTX, LPTX, and TXMDShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Lexaria Bioscience (LEXX), HOOKIPA Pharma (HOOK), Neuphoria Therapeutics (NEUP), Ernexa Therapeutics (ERNA), Synlogic (SYBX), Bullfrog AI (BFRG), MetaVia (MTVA), Briacell Therap (BCTX), Leap Therapeutics (LPTX), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Its Competitors Lexaria Bioscience HOOKIPA Pharma Neuphoria Therapeutics Ernexa Therapeutics Synlogic Bullfrog AI MetaVia Briacell Therap Leap Therapeutics TherapeuticsMD Lexaria Bioscience (NASDAQ:LEXX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations. Does the media favor LEXX or ADIL? In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 1 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.87 beat Lexaria Bioscience's score of 0.63 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Lexaria Bioscience Positive Adial Pharmaceuticals Very Positive Do institutionals & insiders have more ownership in LEXX or ADIL? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 4.3% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate LEXX or ADIL? Lexaria Bioscience currently has a consensus price target of $5.00, indicating a potential upside of 411.25%. Adial Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 1,456.42%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is LEXX or ADIL more profitable? Adial Pharmaceuticals has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. Lexaria Bioscience's return on equity of -157.22% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,849.19% -157.22% -133.69% Adial Pharmaceuticals N/A -218.88%-177.61% Which has better valuation & earnings, LEXX or ADIL? Lexaria Bioscience has higher revenue and earnings than Adial Pharmaceuticals. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$460K41.59-$5.80M-$0.67-1.46Adial PharmaceuticalsN/AN/A-$13.20M-$1.46-0.35 Which has more volatility and risk, LEXX or ADIL? Lexaria Bioscience has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. SummaryAdial Pharmaceuticals beats Lexaria Bioscience on 8 of the 14 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.01M$136.79M$5.70B$9.50BDividend YieldN/A3.74%4.69%4.01%P/E Ratio-0.353.7528.1020.06Price / SalesN/A4,471.55428.7189.10Price / CashN/A13.1936.2258.56Price / Book0.8042.328.665.87Net Income-$13.20M-$90.99M$3.25B$258.55M7 Day Performance13.92%4.82%4.22%3.73%1 Month Performance9.41%8.35%10.51%11.75%1 Year Performance-51.05%195.88%34.40%18.02% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals2.9178 of 5 stars$0.51+7.0%$8.00+1,456.4%-56.1%$5.01MN/A-0.3520Positive NewsAnalyst UpgradeLEXXLexaria Bioscience2.2435 of 5 stars$0.83-5.3%$5.00+499.4%-68.3%$14.65M$460K-1.417HOOKHOOKIPA Pharma3.0625 of 5 stars$1.20+0.8%$4.50+275.0%-85.4%$14.63M$43.95M-0.21160News CoverageNEUPNeuphoria Therapeutics2.2034 of 5 stars$7.70+0.1%$21.00+172.7%N/A$14.48M$15.66M0.00N/ANews CoveragePositive NewsAnalyst UpgradeERNAErnexa Therapeutics1.0934 of 5 stars$1.96+0.5%N/A-92.8%$14.44M$535K-0.2410Positive NewsGap UpSYBXSynlogic1.3119 of 5 stars$1.23+1.2%N/A-5.4%$14.33M$10K-0.4980Positive NewsGap UpBFRGBullfrog AI0.4159 of 5 stars$1.51flatN/A-52.8%$14.22M$60K-1.864MTVAMetaVia2.2605 of 5 stars$0.71-1.1%$7.50+956.5%N/A$13.91MN/A0.008BCTXBriacell Therap2.298 of 5 stars$2.02flat$32.00+1,484.2%-93.1%$13.69MN/A-0.248Positive NewsLPTXLeap Therapeutics2.1055 of 5 stars$0.33+0.1%$3.38+922.4%-83.4%$13.68MN/A-0.1940Positive NewsGap DownTXMDTherapeuticsMD0.4354 of 5 stars$1.17-0.8%N/A-33.5%$13.54M$1.76M0.00420Positive News Related Companies and Tools Related Companies Lexaria Bioscience Alternatives HOOKIPA Pharma Alternatives Neuphoria Therapeutics Alternatives Ernexa Therapeutics Alternatives Synlogic Alternatives Bullfrog AI Alternatives MetaVia Alternatives Briacell Therap Alternatives Leap Therapeutics Alternatives TherapeuticsMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
